With the observation of the bioactivity of PCL scaffolds in vitro, we applied the scaffolds with SPP1 (100 μg·mL−1) and/or CXCL12 (20 μg·mL−1) to treat fracture nonunion in RA mice. Here, SPP1 is linked to rheumatoid arthritis.